Home Alzheimer’s Disease Salma Jabbour, MD, on the Design of the Ongoing KEYNOTE-799 Study

Salma Jabbour, MD, on the Design of the Ongoing KEYNOTE-799 Study

The KEYNOTE-799 study is evaluating pembrolizumab plus concurrent chemoradiation therapy in patients with unresectable, locally advanced, stage III non–small cell lung cancer.

In an interview with CancerNetwork®, Salma Jabbour, MD, chief of Gastrointestinal Radiation Oncology at the Rutgers Cancer Institute of New Jersey, explained the design of the ongoing KEYNOTE-799 study (NCT03631784) which is evaluating pembrolizumab (Keytruda) plus concurrent chemoradiation therapy in patients with unresectable, locally advanced, stage III non–small cell lung cancer.

Transcription:

KEYNOTE-799 is a phase 2, open-label, non-randomized study which evaluated pembrolizumab with concurrent chemoradiation therapy for stage III unresectable non–small cell lung cancer.

In cohort A, patients received carboplatin, paclitaxel, and pembrolizumab for 1 cycle; followed by concurrent chemoradiation therapy…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Lower-Dose Hypofractionated Radiotherapy Schedule Proves Effective for Patients With Locally Advanced Bladder Cancer

Using a hypofractionated schedule of 55 Gy in 20 fractions over 4 weeks to treat patients with locally advanced bladder cancer was noninferior to...

Study Identifies New Biomarker Which Could Predict Response to CD40 Immunotherapy in Pancreatic Cancer

Research published in JCI Insight identified systemic inflammation as a possible resistance mechanism to a CD40–based chemoimmunotherapy in patients with advanced pancreatic cancer.1According to...

Significant Interfacility Variation Found in Implementation of Low-Value Breast Cancer Procedures

A number of facility-level characteristics were associated with the use of low-value breast cancer procedures, and interfacility variation presented an opportunity for formal de-implementation...

KarMMa Trial Results for Ide-Cel in Refractory Myeloma Show Favorable Efficacy

Chimeric antigen receptor (CAR) T-cell therapy with idecabtagene vicleucel (ide-cel) induced responses in almost 75% of patients with multiple myeloma following relpase on multiple...

Recent Comments